epocrates

AAN 2025 annual meeting highlights

April 14, 2025

Lecanemab shows sustained benefits in early Alzheimer's disease

(AAN)— Initial findings from the Clarity AD open-label extension reveal continued cognitive stability and biomarker improvement . . . Read more

GLP-1 RAs and SGLT2 inhibitors may lower dementia risk in T2DM

(JAMA Neurol)— T2DM is a known risk factor for Alzheimer's disease and related dementias. The effect of GLP-1 RAs and SGLT2 inhibitors on this risk has been unknown . . . Read more

How safe are higher folic acid doses in pregnancy?

(AAN)— Folic acid supplementation in pregnancy is known to reduce malformations and improve cognitive outcomes, but concerns have been raised over risks of higher folate doses . . . Read more

Early CPAP use may lower Parkinson’s risk in sleep apnea patients

(AAN)— Starting CPAP therapy within two years of sleep apnea diagnosis may reduce the risk . . . Read more

Inebilizumab shows promise in treating generalized myasthenia gravis

(N Engl J Med)— The monoclonal antibody depletes CD19+ B cells, which play a key role in disease pathogenesis . . . Read more

Tavapadon shows promise as adjunctive therapy for Parkinson's disease

(AAN)— The once-daily, selective D1/D5 partial dopamine agonist significantly increased ON time vs. placebo without troublesome dyskinesia in patients with PD . . . Read more